Lurbinectedin is a chemotherapy drug that has been approved by the US Food and Drug Administration (FDA) for the treatment of metastatic small cell lung cancer (SCLC) in patients who have progressed after prior treatment. [1]

There is some research on the use of lurbinectedin in combination with immunotherapy drugs such as pembrolizumab for the treatment of SCLC. A preliminary study published in the Journal of Thoracic Oncology showed that the combination of lurbinectedin and pembrolizumab was safe and effective in patients with relapsed SCLC who had previously received platinum-based chemotherapy. [2] However, it is important to note that this was a small study with a limited number of patients, and further research is needed to confirm these findings.

In summary, lurbinectedin has been approved for the treatment of metastatic SCLC, but its use in combination with immunotherapy drugs such as pembrolizumab is still being studied. While preliminary results are promising, more research is needed to determine the safety and efficacy of this combination therapy. [1][2][3]

Sources:
[1] https://www.drugpatentwatch.com/p/tradename/LURBINECTEDIN
[2] https://www.cancernetwork.com/view/preliminary-results-show-second-line-lurbinectedin-plus-pembrolizumab-safe-effective-in-relapsed-sclc
[3] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8165873/